Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations

被引:25
|
作者
Hensley, Patrick J. [1 ]
Panebianco, Valeria [2 ]
Pietzak, Eugene [3 ]
Kutikov, Alexander [4 ]
Vikram, Raghu [1 ]
Galsky, Matthew D. [5 ]
Shariat, Shahrokh F. [6 ,7 ,8 ,9 ]
Roupret, Morgan [10 ]
Kamat, Ashish M. [1 ,11 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Sapienza Univ, Rome, Italy
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Fox Chase Canc Ctr, Philadelphia, PA USA
[5] Mt Sinai, New York, NY USA
[6] Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria
[7] Weill Cornell Med Coll, Dept Urol, New York, NY USA
[8] Univ Texas Southwestern, Dept Urol, Dallas, TX USA
[9] Al Ahliyya Amman Univ, Hourani Ctr Appl Sci Res, Amman, Jordan
[10] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, GRC Predict Oncouro 5,Urol, Paris, France
[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源
EUROPEAN UROLOGY ONCOLOGY | 2022年 / 5卷 / 04期
关键词
Clinical staging; Muscle-invasive bladder cancer; Pathologic staging; Transurethral resection of  bladder tumor; Vesical Imaging Reporting and  Data System; Examination under anesthesia; REFINING PATIENT SELECTION; NEOADJUVANT CHEMOTHERAPY; RADICAL CYSTECTOMY; UROTHELIAL CARCINOMA; PATHOLOGICAL STAGE; LYMPHOVASCULAR INVASION; PROGNOSTIC-SIGNIFICANCE; DATA SYSTEM; PREDICTION; SURVIVAL;
D O I
10.1016/j.euo.2022.04.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Context: Bladder cancer prognosis and treatment are heavily dependent on accurate staging. Traditional imaging and pathologic evaluation of transurethral resection (TUR) specimens have been associated with high rates of clinical understaging at the time of radical cystectomy (RC).Objective: We describe current components and limitations of bladder cancer staging for muscle-invasive bladder cancer (MIBC), and discuss the rationale for inclusion of novel biomarkers and imaging modalities to improve diagnostic accuracy.Evidence acquisition: We summarize the data informing MIBC staging accuracy using a nonsystematic review of published literature and provide expert opinion on current and emerging standards in MIBC staging.Evidence synthesis: Nearly 50% of patients undergoing RC are clinically understaged pre-operatively. Components of clinical staging include TUR specimen evaluation, bimanual examination under anesthesia (EUA), and cross-sectional imaging of the chest, abdomen, and pelvis. Complete endoscopic resection of visible disease with sampling of muscularis propria is indicated. While histologic features such as tumor size, focality, variant histo-logic differentiation, and lymphovascular invasion have prognostic utility, insufficient evidence exists to incorporate them into current staging paradigms. For primary tumor staging, conventional computed tomography (CT) has limited accuracy in differentiating non-MIBC from MIBC. Magnetic resonance imaging (MRI) has exhibited superior pT stag -ing accuracy with the validated Vesical Imaging Reporting and Data System. Positron emission tomography (PET)/CT does not increase clinical nodal staging accuracy beyond CT or MRI, and there exists no consensus role for the use of PET in routine clinical staging. Conclusions: In the absence of reliable biomarkers to serve as staging adjuncts, we con-tinue to rely heavily on basic clinical staging components-TUR with accurate pathologic evaluation, EUA, and standard cross-sectional imaging modalities. MRI shows promising accuracy and interobserver reliability for primary tumor staging. Patient summary: Effective clinical staging for muscle-invasive bladder cancer estimates local and systemic disease burden and can dictate eligibility for systemic therapy and/or radical cystectomy. Herein, we review the accuracy and limitations of current and emerg-ing staging modalities.(c) 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:403 / 411
页数:9
相关论文
共 50 条
  • [21] Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer
    Konieczkowski, David J.
    Efstathiou, Jason A.
    Mouw, Kent W.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (03) : 567 - 584
  • [22] Downstream Studies Following the Use of Bone Scan in the Staging of Muscle-invasive Bladder Cancer
    Maganty, Avinash
    Turner, Robert M., II
    Yabes, Jonathan G.
    Davies, Benjamin J.
    Heron, Dwight E.
    Jacobs, Bruce L.
    UROLOGY, 2019, 129 : 74 - 78
  • [23] DOWNSTREAM PROCEDURES FOLLOWING THE USE OF BONE SCAN IN THE STAGING OF MUSCLE-INVASIVE BLADDER CANCER
    Turner, Robert, II
    Yabes, Jonathan
    Davies, Benjamin
    Heron, Dwight
    Jacobs, Bruce
    JOURNAL OF UROLOGY, 2017, 197 (04): : E591 - E592
  • [24] Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer
    Singh, Amisha
    Osbourne, Appledene S.
    Koshkin, Vadim S.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (09) : 1213 - 1230
  • [25] Actionable mutations in muscle-invasive bladder cancer
    Bambury, Richard M.
    Rosenberg, Jonathan E.
    CURRENT OPINION IN UROLOGY, 2013, 23 (05) : 472 - 478
  • [26] Organ preservation in muscle-invasive bladder cancer
    Fernando, Shaneli A.
    Sandler, Howard M.
    ONCOLOGY-NEW YORK, 2005, 19 (03): : 334 - 339
  • [27] Muscle-Invasive Bladder Cancer and Radical Cystectomy
    Hakenberg, Oliver W.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (01) : 1 - 1
  • [28] Molecular Biomarkers in Muscle-Invasive Bladder Cancer
    Choudhury, Ananya
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 92 (04): : 705 - 706
  • [29] Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
    Peyrottes, Arthur
    Ouzaid, Idir
    Califano, Gianluigi
    Hermieu, Jean-Francois
    Xylinas, Evanguelos
    MEDICINA-LITHUANIA, 2021, 57 (08):
  • [30] Current management of muscle-invasive bladder cancer
    Gemma Sancho
    Pablo Maroto
    Joan Palou
    Clinical and Translational Oncology, 2011, 13 : 855 - 861